Haleh Saber - Concepedia

Author

Haleh Saber

United States Food and Drug Administration

Also Known As

H. Saber, Haleh Saber, hamada salah saber

Publications

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research

About

Haleh Saber is an author at United States Food and Drug Administration specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	985
2	Health Sciences	5	5	447
3	Education	2	2	23
4	Engineering	1	1	145
5	Civil Engineering	1	1	145

Haleh Saber

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate Michael H. Brave, Vicki Goodman, Edvardas Kaminskas, Clinical Cancer Research	2008	239
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski, Clinical Cancer Research Lymphoid NeoplasiaTranslational MedicineHodgkin LymphomaU.s. FoodMedicine	2012	207
An FDA oncology analysis of antibody-drug conjugates Haleh Saber, John K. Leighton Regulatory Toxicology and Pharmacology Polymer-drug ConjugateMedicinePharmacologyAntibody EngineeringAntibody-drug Conjugates	2015	166
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia R. Angelo de Claro, Karen M. McGinn, Nicole Verdun, Clinical Cancer Research Preclinical TherapeuticsTyrosine KinasePathologyFda ApprovalPharmacotherapy	2015	156
Identification and interpretation of complexity in sedimentation velocity boundaries Borries Demeler, Haleh Saber, Jeffrey C. Hansen Biophysical Journal EngineeringSedimentationGeomorphologyDebris FlowCivil Engineering	1997	145
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis Albert Deisseroth, Edvardas Kaminskas, Joseph A. Grillo, Clinical Cancer Research Hematological MalignancyAntifibrotic TherapyOncologyU.s. FoodMetronomic Therapy	2012	143
FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation Michael H. Brave, Ann T. Farrell, Sue Ching Lin, Oncology	2010	140
U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia Firoozeh Alvandi, Virginia E. Kwitkowski, Chia‐Wen Ko, The Oncologist PharmacotherapyPre-clinical PharmacologyMyeloid NeoplasiaHematological MalignancyTranslational Medicine	2013	96
An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates Haleh Saber, Natalie E. Simpson, Tiffany K. Ricks, Regulatory Toxicology and Pharmacology Fda Oncology AnalysisDrug TargetingOncologyPolymer-drug ConjugateMedicine	2019	85
An FDA oncology analysis of immune activating products and first-in-human dose selection Haleh Saber, Ramadevi Gudi, Michael L. Manning, Regulatory Toxicology and Pharmacology Fda Oncology AnalysisCancer ImmunosurveillanceMedicineFirst-in-human Dose SelectionImmunology	2016	51

Page 1